# VHT Fact Sheet

Vanguard Health Care ETF

**$326.69**
close, Nov 20, 2026

Over the year to Nov 19, 2026, VHT returned +17.5% in total and charged 0.09% a year.

| 1-year total return | Expense ratio | Net assets |
|---|---|---|
| **+17.8%** | **0.09%** | **$20.8bn** |
| FHLC +17.9% to Nov 20, 2026 | a year | on Oct 31, 2026 |

## Growth of $10,000, 1 year




VHT **$11,753** +17.5% · FHLC **$11,765** +17.6% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

## Returns

| WINDOW | TOTAL RETURN |
|---|---|
| 1 month | **-1.7%** |
| 3 months | **0.0%** |
| Year to date | **+14.7%** |
| 1 year | **+17.8%** |
| 3 years | **+45.0%** |
| 5 years | **+37.4%** |

Total return, distributions reinvested, each window to Nov 20, 2026.

## Ten largest positions

| HOLDING | WEIGHT |
|---|---|
| Eli Lilly & Co | **14.69%** |
| Johnson & Johnson | **8.40%** |
| AbbVie Inc | **6.74%** |
| UnitedHealth Group Inc | **4.78%** |
| Merck & Co Inc | **4.78%** |
| Thermo Fisher Scientific Inc | **3.35%** |
| Amgen Inc | **3.25%** |
| Gilead Sciences Inc | **2.74%** |
| Abbott Laboratories | **2.39%** |
| Pfizer Inc | **2.25%** |

VHT top ten by weight, 53.4% of the fund, of its 410 equity positions, from the holdings filed for Oct 31, 2026.

## Facts

Equity fund · Tracks the MSCI US Investable Market Index (IMI)/Health Care 25/50 · First traded Jan 30, 2004 · Benchmark MSCI US Investable Market Index (IMI)/Health Care 25/50, measured by FHLC, which tracks the same index

ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/vht.